Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AB801

Phase 1Small molecule

Arcus Biosciences

AB801 is one of 43 small molecule programs targeting Advanced Cancer. It is currently in Phase 1.

1

Indications

2

Total Trials

1

Active Trials

42

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced CancerActive, not recruiting

Advanced CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

67 competitors in Advanced Cancer

#DrugCompanyPhaseTrials

Keytruda

Taxol

Gemzar

Johnson & Johnson

Camptosar

Opdivo

Bristol-Myers Squibb

Verzenio

Elunate

Taxotere

Torisel

PPrism Pharmaceuticals

Paraplatin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Advanced Cancer

NCT06120075

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT06004921·32 enrolled

Advanced Cancer1 trial

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Active, not recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT06120075·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AB801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arcus Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Arcus Biosciences

Related News